Diltiazem: ten years of clinical experience in the treatment of hypertension
- PMID: 7608309
- DOI: 10.1002/j.1552-4604.1995.tb04051.x
Diltiazem: ten years of clinical experience in the treatment of hypertension
Abstract
Diltiazem hydrochloride is a benzothiazepine derivative calcium-channel blocker with proven antianginal and antihypertensive capabilities. Its primary mechanism of action is vasodilatation, which results in diminished vascular resistance and improved perfusion to various vascular beds and target organs. The antihypertensive efficacy of diltiazem in various demographic groups has been studied and compared with diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and other calcium-channel blockers. These studies have shown that the antihypertensive effect of diltiazem is similar to that of the other therapies. Diltiazem does not adversely affect electrolytes or carbohydrate or lipid metabolism, and it may have beneficial effects on the heart and kidneys. Diltiazem reduces myocardial hypertrophy and exerts antianginal effects on the heart through coronary vasodilation and reduction in the blood pressure double product. Diltiazem improves renal perfusion and attenuates proteinuria. These effects may be helpful in limiting the progression of renal injury. Overall, the efficacy and tolerability of diltiazem, as well as its salutary effects on the heart and kidneys, make it an important therapeutic consideration for patients with hypertensive disease.
Similar articles
-
Diltiazem: its place in the antihypertensive armamentarium.J Cardiovasc Pharmacol. 1991;18 Suppl 9:S26-31. J Cardiovasc Pharmacol. 1991. PMID: 1725539 Review.
-
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.Clin Exp Hypertens. 2006 Oct;28(7):655-62. doi: 10.1080/10641960600946429. Clin Exp Hypertens. 2006. PMID: 17060064 Clinical Trial.
-
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.Cardiovasc Drugs Ther. 1993 Apr;7(2):193-206. doi: 10.1007/BF00878508. Cardiovasc Drugs Ther. 1993. PMID: 8395198
-
Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.Lancet. 2000 Jul 29;356(9227):359-65. doi: 10.1016/s0140-6736(00)02526-5. Lancet. 2000. PMID: 10972367 Clinical Trial.
-
Calcium-channel blocking agents.Clin Pharm. 1982 Jan-Feb;1(1):17-33. Clin Pharm. 1982. PMID: 6764159 Review.
Cited by
-
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.Cardiovasc Drugs Ther. 2023 Dec;37(6):1205-1223. doi: 10.1007/s10557-022-07334-y. Epub 2022 Mar 31. Cardiovasc Drugs Ther. 2023. PMID: 35357604 Review.
-
Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration.Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):27-31. doi: 10.1007/BF03189823. Eur J Drug Metab Pharmacokinet. 1998. PMID: 9625269
-
Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung.PLoS Pathog. 2022 Feb 17;18(2):e1010343. doi: 10.1371/journal.ppat.1010343. eCollection 2022 Feb. PLoS Pathog. 2022. PMID: 35176124 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical